Voltage-gated sodium (Na v ) channels play a fundamental role in the generation and propagation of electrical impulses in excitable cells. Here we describe two unique structurally related nanomolar potent small molecule Na v channel inhibitors that exhibit up to 1,000-fold selectivity for human Na v 1.3/Na v 1.1 (ICA-121431, IC 50 , 19 nM) or Na v 1.7 (PF-04856264, IC 50 , 28 nM) vs. other TTX-sensitive or resistant (i.e., Na v 1.5) sodium channels. Using both chimeras and single point mutations, we demonstrate that this unique class of sodium channel inhibitor interacts with the S1-S4 voltage sensor segment of homologous Domain 4. Amino acid residues in the "extracellular" facing regions of the S2 and S3 transmembrane segments of Na v 1.3 and Na v 1.7 seem to be major determinants of Na v subtype selectivity and to confer differences in species sensitivity to these inhibitors. The unique interaction region on the Domain 4 voltage sensor segment is distinct from the structural domains forming the channel pore, as well as previously characterized interaction sites for other small molecule inhibitors, including local anesthetics and TTX. However, this interaction region does include at least one amino acid residue [E1559 (Na v 1.3)/ D1586 (Na v 1.7)] that is important for Site 3 α-scorpion and anemone polypeptide toxin modulators of Na v channel inactivation. The present study provides a potential framework for identifying subtype selective small molecule sodium channel inhibitors targeting interaction sites away from the pore region.
V oltage-gated sodium (Na v ) channels play an important role in the generation and propagation of electrical signals in excitable cells (1) (2) (3) . Eukaryotic Na v channels are heteromeric membrane proteins composed of a pore-forming α-subunit and auxiliary β-subunits (3, 4) . The mammalian genome encodes nine distinct α (Na v 1.1-1.9) and four β subunits (3) . The α-subunit comprises four homologous domains (D1-D4), each of which contains six transmembrane segments (S1-S6) (3) (4) (5) . The S5 and S6 segments form the central pore separated by the SS1 and SS2 segments, which form the ion selectivity filter at its extracellular end. The S1 to S4 segments form the voltage sensor (3) (4) (5) .
Both naturally occurring and synthetic pharmacological modulators of sodium channel have been identified (6) (7) (8) (9) (10) (11) , and for many, their site of interaction has been defined. For example, the marine toxin TTX inhibits several Na v subtypes by interacting with amino acid residues within the SS1-SS2 segments that define the outer pore of the channel (12, 13) . In contrast, the polypeptide α-and β-scorpion venom toxins, which enhance sodium channel activation or delay inactivation, and spider venom toxin sodium channel inhibitors like Protx II interact with specific residues on the S1-S4 voltage sensor regions within homologous Domain 2 (i.e., β-scorpion toxins, Protx II) or Domain 4 (i.e., α-scorpion toxins, anemone toxins) of the channel (8, (14) (15) (16) (17) (18) . Many synthetic small molecule inhibitors of Na v channels, including local anesthetic, antiepileptic, and antiarrhythmic agents, are believed to interact with amino acid residues within the S6 segment in Domain 4, which forms part of the pore lining and is structurally highly conserved across subclasses of mammalian Na v channels (11, (19) (20) (21) (22) . This structural homology probably accounts for many clinically used local anesthetics and related antiepileptic and antiarrhythmic inhibitors, exhibiting little or no selectivity across the nine subtypes of mammalian Na v channels (23) . In the clinic this absence of subtype selectivity can result in toxicities associated with unwanted interactions with off-target Na v channels (e.g., cardiac toxicity due to inhibition of cardiac Na v 1.5 channels) (24, 25) . Therefore, because of their importance in normal physiology and pathophysiology, identification of selective pharmacological modulators of Na v channels is of considerable interest to the scientific and medical communities (9, 23, (26) (27) (28) (29) . For example, in addition to the therapeutic utility of sodium channel inhibitors described above, there has been recent interest in potentially targeting inhibition of specific Na v channel subtypes (i.e., Na v 1.7, Na v 1.8, and Na v 1.3) for the treatment of pain (9, (30) (31) (32) .
The present study describes the characterization of a class of subtype selective sodium channel inhibitor that interacts with a unique site on the voltage sensor region of homologous Domain 4. This inhibitory interaction site differs from previously reported inhibitor binding sites for TTX and local anesthetic-like modulators (11, 12) .
Significance
Voltage-gated sodium (Na v ) channels contribute to physiological and pathophysiological electrical signaling in nerve and muscle cells. Because Na v channel isoforms exhibit tissue-specific expression, subtype selective modulation of this channel family provides important drug development opportunities. However, most available Na v channel modulators are unable to distinguish between Na v channel subtypes, which limits their therapeutic utility because of cardiac or nervous system toxicity. This study describes a new class of subtype selective Na v channel inhibitors that interact with a region of the channel that controls voltage sensitivity. This interaction site may enable development of selective therapeutic interventions with reduced potential for toxicity.
Results
Characterization of a Subtype Selective Inhibitor of Human Na v 1.3 Channels. During a Na v channel inhibitor drug candidate discovery program, a previously uncharacterized agent, ICA-121431 [2,2-diphenyl-N-(4-(N-thiazol-2-ylsulfamoyl)phenyl) acetamide] was found to inhibit human TTX-sensitive Na v 1.3 sodium channels stably expressed in HEK-293 cells (Fig. 1A) . As with many known voltage-dependent sodium channel inhibitors, inhibition of human Na v 1.3 by ICA-121431 was found to be dependent on channel gating state. When Na v 1.3 currents were elicited by 20-ms depolarizing voltage steps from −120 mV, at which channels are predominantly in a resting closed state, ICA-121431 had a negligible effect on current amplitude at 1 μM (Fig. 1B) . In contrast, when a test pulse was preceded by an 8-s conditioning voltage step to a membrane potential that resulted in approximately half of the channels being in an inactivated state, 1 μM ICA-121431 produced 92% ± 4% (n = 4) reduction in current amplitude (Fig. 1B) . A preferential interaction with inactivated Na v 1.3 channels was further supported by the finding that ICA-121431 elicited a concentration-dependent hyperpolarizing shift in the voltage dependence of inactivation (Fig. 1C) .
Although ICA-121431 produced negligible inhibition when test pulses were applied from a −120 mV holding potential at a relatively low stimulation frequency (i.e., 0.05 Hz), cumulative (or usedependent) inhibition became evident when stimulation frequency was increased to 10 Hz (Fig. 1D ). This use-dependent inhibition of Na v 1.3 by ICA-121431 clearly differs from the absence of frequency-dependent inhibition in the presence of TTX (Fig. 1D) .
Although state-and/or frequency-dependent inhibition is a relatively common characteristic of small molecule voltage-gated sodium channel inhibitors (33), a more unique finding was the marked subtype selectivity exhibited by ICA-121431. Fig. 1E shows that in contrast to Na v 1.3, 1 μM ICA-121431 produced little or no inhibition of human Na v 1.7 or Na v 1.5 currents. Selective inhibition of Na v 1.3 by ICA-121431 is further illustrated in Fig. 1F , which shows the concentration dependence of inhibition of human Na v 1.3, Na v 1.5, and Na v 1.7 measured on the IonWorks Quattro automated electrophysiology using a 500-ms conditioning pulse to 0 mV to promote availability of the inactivated state. Under these conditions, the IC 50 for ICA-121431 inhibition of Na v 1.3 was 19 ± 5 nM (n = 6), compared with >10 μM for both human Na v 1.5 and Na v 1.7. When additional Na v channel subtypes were examined, the selectivity profile of ICA-121431 was found to cover a spectrum of inhibitor potencies, with human Na v 1.3 and Na v 1.1 being the most sensitive to inhibition (IC 50 s <20 nM), Na v 1.2 having an intermediate sensitivity (IC 50 240 nM), whereas Na v 1.4, Na v 1.5, Na v 1.6, Na v 1.7, and Na v 1.8 were relatively insensitive to inhibition (IC 50 s >10 μM) ( Fig. S1 and Table S1 ). 50 18 ± 5 nM (n = 6) for Na v 1.3 and >10 μM for Na v 1.5 (n = 4) and Na v 1.7 (n = 6), respectively]. Inhibition of sodium currents was recorded on IonWorks Quattro using a protocol comprising a 500-ms step from −120 mV to 0 mV to inactivate the channels, followed after a 100-ms recovery at −100 mV by a 20-ms test pulse to 0 mV to define inhibition.
amino acid residues that may define selectivity for this channel over other related Na v channels, including Na v 1.7 and Na v 1.5. Our initial attempts focused on establishing whether inhibition resulted from interaction with a specific domain of the sodium channel. Restriction sites were introduced into the nucleotide sequences between the Domain 1-4 repeats of Na v 1.3, Na v 1.7, and Na v 1.5 (details of sites in Fig. S2 ). Chimeras of Na v 1.3 domains combined with varying homologous domains of either Na v 1.7 or Na v 1.5 were constructed and expressed in HEK-293 cells and then evaluated for inhibition by ICA-121431 using the 8-s half inactivation pulse protocol on conventional patch clamp described previously. Fig. 2A shows that replacement of Domain 3 and 4 of Na v 1.3 with the equivalent domains from Na v 1.7 resulted in a chimeric channel (Domains 1-4 = 3,3,7,7) that exhibited very weak sensitivity to inhibition by ICA-121431 (12% ± 4% at 3 μM, n = 3). This data suggested that the interaction site may lie somewhere within homologous Domains 3 and 4. Another chimera in which only Domain 4 of Na v 1.3 was replaced with the equivalent domain from Na v 1.5 (Domains 1-4 = 3,3,3,5) also lacked sensitivity to inhibition by ICA-121431 (19% ± 4% at 3 μM, n = 3). These findings suggest that Domain 4 may contain an interaction site for ICA-121431 inhibition. Further support of this hypothesis was demonstrated when a chimera comprising Domains 1-3 of Na v 1.5 and Domain 4 of Na v 1.3 (Domains 1-4 = 5,5,5,3) exhibited relatively potent inhibition by ICA-121431 (45% ± 2% at 0.1 μM and 90% ± 3% at 1 μM, n = 2) ( Fig. 2A) , which is ∼fivefold less potent than Na v 1.3 but more than 500-fold more potent than inhibition of Na v 1.5. It further suggests that the entire ICA-121431 interaction site may be contained within Domain 4 of Na v 1.3. It should be noted that the chimeras described above do exhibit significant differences in the voltage dependence of inactivation relative to unmodified Na v 1.3 (midpoints potentials of −73 ± 1 mV for 3,3,7,7 chimera, −67 ± 1 mV for 3,3,3,5 chimera; −82 ± 2 mV for 5,5,5,3 chimera compared with −58 ±1 mV for wild-type Na v 1.3). However, we believe that by using an 8-s conditioning pulse to the midpoint of inactivation protocol set appropriately for each of the chimeras being evaluated, we minimized the contribution of differences in voltage dependence of inactivation to apparent potency differences. Support for this comes from the finding that 1 μM amitriptyline [a nonselective Na v channel inhibitor that interacts preferentially with inactivated channels (34) ] produced relatively similar inhibition of the chimeras compared with unmodified Na v 1.3; 40% for 3,3,7,7 chimera, 60% for 3,3,3,5 chimera; 35% for 5,5,5,3 chimera compared with 51% for wild-type Na v 1.3 (less than threefold differences in estimated IC 50 s). . Inhibition of sodium currents in B, C, and D were recorded using conventional patch clamp and determined using an 8-s conditioning voltage step from −120 mV to a voltage producing half-maximal inactivation followed after a 20-ms recovery at −100 mV by a 20-ms test pulse to 0 mV. Domain 4 voltage sensor region S1-S4 of Na v 1.3 with the same region from Na v 1.5 (S1-S4) resulted in a >500-fold loss potency for inhibition by ICA-121431 (IC 50 10 ± 2 μM, n = 3) (Fig. 2 B-D) , indicating that the main interaction site for ICA-121431 probably lies within the voltage sensor region. To further delineate possible interaction sites within the Domain 4 S1-S4 voltage sensor region, three additional chimeras were constructed, in which either the S1, S2, or S3-S4 transmembrane segments or associated loops from Domain 4 of the Na v 1.3 were replaced with the equivalent amino acid sequences of Na v 1.5 or Na v 1.7 ( Fig. 2 B and C) . Fig. 2D shows that whereas replacing S1 of Na v 1.3 with S1 from Na v 1.5 or Na v 1.7 produced a relatively small (three-to eightfold) reduction in inhibition potency, replacement of either S2 or S3-S4 with the Na v 1.5 or Na v 1.7 sequence resulted in 20-to 100-fold loss in sensitivity to inhibition by ICA-121431 (IC 50 s for different chimeras are summarized in Table S2 ).
Three Amino Residues in the Voltage Sensor Region Contribute to
Selectivity of ICA-121431. To identify specific amino acid residues within the S2-S4 region of Domain 4 that contribute to ICA-121431 selective inhibition, we aligned human Na v channel amino acid sequences of Domain 4 S1-S4 and then grouped by relative sensitivity to inhibition. As noted earlier, the two most sensitive channels were Na v 1.3 and Na v 1.1. Na v 1.2 exhibited an intermediate sensitivity (IC 50 240 nM), whereas Na v 1.4, Na v 1.5, Na v 1.6, Na v 1.7, and Na v 1.8 were relatively insensitive to inhibition (IC 50 s >10 μM) (Fig. 3A, Fig. S1 , and Table S1 ).
A B C D Residues that were present in ICA-121431 sensitive channels but absent in insensitive sodium channels (highlighted in yellow) were mutated, substituting in equivalent residues from Na v 1.7 (termed M1, M2, and M3). The location of the chimera constructs D4 S1, D4 S2, and D4S3-S4 described in 3. Data were generated using conventional patch clamp using an 8-s conditioning voltage step from −120 mV to a voltage producing half-maximal inactivation followed after a 20-ms recovery at −100 mV by a 20-ms test pulse to 0 mV.
Focusing on the S2-S4 region of Domain 4, we looked for amino acid residues shared between Na v 1.3 and Na v 1.1 and not most other Na v channels. Three residues were identified: consecutive serine and arginine residues at positions 1510 and 1511 and a glutamate at position 1559 in S3 of Na v 1.3 (Fig. 3A) . S1510, R1511, and E1559 are predicted to be at the extracellular ends of the S2 and S3 transmembrane segments and were therefore initially considered to be promising candidates for potential ligand interaction. To examine their role, individually and together, these Na v 1.3 residues were replaced with the equivalent residues of the ICA-121431-insensitive Na v 1.7 channel. The effects of these mutations on inhibition by ICA-121431 are shown in Fig. 3B (also refer to Table S2 ). S1510Y (M1) resulted in a ninefold loss of potency of ICA-121431, whereas R1511W (M2) and E1559D (M3) produced 33-fold and 97-fold reductions in potency, respectively. The double mutation R1511W/E1559D (M2,3) produced a 152-fold loss of potency, whereas the triple mutation S1510Y/R1511W/E1559D (M1,2,3) resulted in a 600-fold loss of potency, exhibiting a lack of sensitivity to inhibition by ICA-121431 similar to Na v 1.7. These results suggest that all three identified residues on Na v 1.3 play a role in defining inhibition by ICA-121431. Although variations in the voltage dependence of inactivation for the various mutants were observed (Fig. S2) , for the most part they were <7 mV and there was no obvious correlation with the widely varying potencies seen with ICA-121431. Moreover, all of the individual (M1, M2, M3) and multiple mutants (M2,3 and M1,2,3) of Na v 1.3 exhibited relatively constant sensitivities to inhibition by amitriptyline (IC 50 ∼1 μM) (Fig.  3 C and D) , which as mentioned earlier would be expected to exhibit similar sensitivity to differences in the voltage dependence of inactivation as ICA-121431.
An obvious next question is whether the S1510/R1511/E1559 residues are sufficient to account for the selectivity of ICA-121431 for Na v 1.3 over Na v 1.7. To address this question, a triple mutation of Na v 1.7 was made in which residues corresponding to M1, M2, and M3 were replaced by the equivalent Na v 1.3 residues (Y1537S/W1538R/D1586E; Na v 1.7 M1,2,3). Fig. 4A , Left compares ICA-121431 inhibition of Na v 1.7 M1,2,3 with Na v 1.3 M1,2,3, wild-type Na v 1.3, and Na v 1.7. Replacement of the three residues on Na v 1.7 with those from Na v 1.3 resulted in an 860-fold increase in potency for inhibition by ICA-121431; Na v 1.7 M1,2,3 exhibited an IC 50 of 33 nM, which is within twofold of the IC 50 of 18 nM for unmodified Na v 1.3. Furthermore, in contrast to the dramatic effects of Na v 1.7 M1,2,3 and Na v 1.3 M1,2,3 on ICA-121431 inhibition, these mutations had little or no effect on inhibition by the local anesthetic tetracaine (Fig. 4A, Right) . Moreover, the M1,2,3 mutant forms of either Na v 1.3 or Na v 1.7 were associated with only minimal changes in biophysical properties, such as voltage dependence of activation (Fig. 4 B and C) , inactivation (Fig. 4 D and E) , and rate of recovery from inactivation (Fig. 4 F and G) (Table S3 lists biophysical parameters). These nominal biophysical differences are unlikely to account for the profound changes in pharmacological sensitivity seen in the mutated channels. Therefore, taken together, the evidence suggests that the S1510/R1511/E1559 residues in the Domain 4 voltage sensor region of Na v 1.3 contribute to the potent and selective inhibition of Na v 1.3 (and Na v 1.1) by ICA-121431 by affecting the physical interaction of the molecule.
The Same Three Amino Residues Can Contribute to Human Na v 1.7
Inhibitor Selectivity. The selectivity profile of ICA-121431, along with amino acid sequence diversity among Na v family members , and M3 residues of Na v 1.3 with residues from Na v 1.7 (i.e., S1510Y/R1511W/E1559D) or vice versa in which the equivalent M1, M2, and M3 residues of Na v 1.7 are substituted with equivalent residues from Na v 1.3 (i.e., Y1537S/W1538R/D1586E). Inhibition was recorded using the IonWorks Quattro using the protocol described in Fig. 1F Table S3 . Data were generated using the PatchXpress automated electrophysiology platform.
around the proposed interaction site (Fig. 3A) , raises the question of whether this region of Na v channels provides opportunities for finding inhibitors with selectivity for other Na v channel subtypes. This question was addressed with another aryl sulphonamido-thiazole-containing molecule, PF-04856264 [3-cyano-4-(2-(1-methyl-1H-pyrazol-5-yl) phenoxy)-N-(thiazol-2-yl) benzenesulfonamide] (Fig. 5A) , which was identified during a screen for Na v 1.7 inhibitors. PF-04856264 was observed to interact preferentially with the inactivated state of Na v 1.7. Fig. 5B shows that Na v 1.7 currents elicited by 20-ms depolarizing voltage steps from −120 mV were insensitive to inhibition by 1 μM PF-04856264, whereas the same concentration produced 91% ± 4% inhibition when a test pulse was preceded by an 8-s conditioning voltage step to inactivate approximately half of the channels. Interestingly, using this latter protocol, human Na v 1.3 and Na v 1.5 exhibited little or no sensitivity to inhibition by 1 μM PF-04856264 (Fig. 5C ). The subtype selectivity exhibited by PF-04856264 is further illustrated in the concentration response curves shown in Fig. 5D (generated using the same protocol used for ICA-121431 in Fig. 1D ). The fitted IC 50 for inhibition of human Na v 1.7 was 28 ± 5 nM (n = 8), whereas little or no inhibition of human Na v 1.3 or Na v 1.5 currents were observed at concentrations up to 10 μM. Given the structural similarity (i.e., aryl sulphonamido-thiazole moiety) between PF-04856264 and ICA-121431, we evaluated the importance of the Domain 4 voltage sensor M1,2,3 residues of Na v 1.7 for PF-04856264 inhibitor activity. Fig. 5E shows that when the M1,2,3 equivalent residues on Na v 1.7 were substituted with residues found in Na v 1.3 (i.e., Y1537S/W1538R/ D1586E), inhibition by PF-04856264 was essentially abolished (IC 50 >10 μM). The specificity of this modulatory effect is highlighted by the finding that inhibition by other established sodium channel blocking agents, tetracaine and TTX, which reportedly bind within or over the pore, was not changed by the Y1537S/W1538R/D1586E substitution (Fig. 5 F and G) . Furthermore, Fig. 5 E and F provide supporting evidence that PF-04856264 and local anesthetic-like inhibitors interact with distinct binding sites, because mutation of two residues (F1737A/ Y1744A) in S6 of Domain 4 of Na v 1.7, which are reported to be involved in local anesthetic and antiepileptic drug binding to Na v channels (19, 20) , resulted in a >100-fold loss of potency for inhibition by tetracaine (IC 50 >100 μM compared with 0.9 μM for wild-type Na v 1.7) but only a nominal change in the potency of PF-04856264 (IC 50 = 12 nM compared with 28 nM for wildtype Na v 1.7).
To further evaluate whether the M123 Y1537/W1538/D1586 amino acid motif was sufficient to account for the Na v 1.7 vs. Na v 1.3 selectivity observed with PF-04856264, a construct was generated in which the equivalent residues of human Na v 1.3 were replaced with the Na v 1.7 M123 residues (S1510Y/R1511W/ E1559D). The potency for inhibition of Na v 1.3 M123 (S1510Y/ R1511W/E1559D) by PF-04856264 was found to be 7 μM. Although this IC 50 is measurably lower than for Na v 1.7 M123 (Y1537S/W1538R/D1586E), it is 250-fold greater than the IC 50 for wild-type Na v 1.7. These findings suggest that although the M123 residues are important for PF-04856264 inhibition of Na v 1.7, they are not sufficient to account for all of the subtype selectivity observed with this particular inhibitor, indicating that additional residues in this region may play a role in determining subtype selective interactions.
Species Dependent Inhibition by ICA-121431 and PF-04856264 Is Determined by Amino Acid Sequence Differences in Domain 4
Voltage Sensor Region. Although we have shown that ICA-121431 and PF-04856264 exhibit selectivity for human Na v 1.3 or human Na v 1.7, this profile was not observed with all mammalian species evaluated. For example, whereas cynomolgus monkey and dog Na v 1.7 lacked sensitivity to inhibition by ICA-121431 (IC 50 s > 5,000 nM) similar to human Na v 1.7, we found that rat currents by PF-04856264 (IC 50 is 28 ± 5 nM for Na v 1.7 and >10 μM for Na v 1.3 and Na v 1.5). (E) PF-04856264 mediated inhibition of unmodified (WT) Na v 1.7, Na v 1.7 M1,2,3 (Y1537S/W1538R/D1586E), or the local anesthetic binding site mutant Na v 1.7(F1737A/Y1744A) (LA) compared with inhibition by the local anesthetic tetracaine (F) or TTX (G). IC 50 s are provided in the text. Data for D-G were generated on the IonWorks Quattro using the protocol described in Fig. 1F . Na v 1.7 is potently inhibited by ICA-121431 with an IC 50 of 19 nM, which is more comparable to its inhibition of human Na v 1.3 (i.e., >1,000-fold more potent than human Na v 1.7) (Fig. 6A) . However, mouse Na v 1.7 gave a more human-like profile, with an IC 50 for inhibition by ICA-121431 of 8,700 nM. Intriguingly, an opposite differential rodent sensitivity to inhibition was observed with the human Na v 1.7-selective inhibitor PF-04856264 (Fig.  6B) . Whereas the IC 50 s for PF-04856264 inhibition of cynomolgus monkey (19 nM) or dog Na v 1.7 (42 nM) were comparable to human Na v 1.7, rat Na v 1.7 was considerably less sensitive, exhibiting an IC 50 of 4,200 nM. Again, in contrast to rat, mouse Na v 1.7 exhibited a higher sensitivity to inhibition by PF-04856264 (IC 50 131 nM) .
The amino acid sequence alignments of the Domain 4 S1-S4 transmembrane segments from Na v 1.7 for different species shown in Fig. 6C provide a possible explanation for the variation in species sensitivities to inhibition by ICA-121431 or PF-04856264. Although there is a high degree of sequence homology across species in this region, there are notable variations including those in the M1, M2, or M3 residues (i.e., human Na v 1.7-Y1537/W1538/D1586), which have been shown in previous sections to be important for defining human Na v 1.3 and Na v 1.7 selectivity. Specifically, species exhibiting the most human-like Na v 1.7 inhibition profile (i.e., cynomolgus monkey, dog, and mouse Na v 1.7) also exhibited the highest sequence homology over these three residues. In contrast, rat Na v 1.7 differs at both the M1 and M3 residues.
Discussion
In the present study we characterize a unique class of nanomolar potent small molecule inhibitors of Na v channels that interact with and stabilize inactivated states of the channel. Furthermore, structurally related compounds within this class exhibit subtype selective inhibition of Na v channels, including human Na v 1.3 and Na v 1.7. For example, ICA-121431 exhibited a spectrum of inhibitory activity for Na v human channel subtypes; equipotent inhibition of Na v 1.3 and Na v 1.1, less potent inhibition of Na v 1.2, and much weaker inhibition of Na v 1.7, Na v 1.6, Na v 1.4, and the TTX-resistant human Na v 1.5 and Na v 1.8 channels (IC 50 s >10 μM). We exploited the subtype selectivity of ICA-121431 to investigate possible Na v interaction sites by constructing Na v 1.3/Na v 1.5 or Na v 1.7 chimeras. Functional evaluation of these chimeras has provided evidence that the likely site of interaction for this class of inhibitor is at extracellular ends of the S2 and S3 transmembrane segments of Domain 4. By comparing the amino acid sequences of ICA-121431 sensitive vs. insensitive Na v channel subtypes over this region of the voltage sensor, we have identified three unique residues found only in channels sensitive to inhibition by ICA-121431[S1510 (M1), R1511 (M2), and E1559 (M3) of Na v 1.3] . Their replacement with equivalent residues from the ICA-121431-insensitive Na v 1.7 channel reduced potency for Na v 1.3 inhibition by >500-fold. Further compelling evidence that the M1,2,3 residues are primary contributors to selective inhibition of Na v 1.3 by ICA-121431 came from substituting the three M1,2,3 residues in human Na v 1.7 with the Na v 1.3 equivalent residues (Y1537S/W1538R/D1586E), which resulted in a striking gain in sensitivity to inhibition, comparable to unmodified Na v 1.3. Although each of the M1, M2, or M3 residues contribute to inhibition, modification of the M2 and M3 residues alone and in combination had the largest impact on potency of ICA-121431. The M1,2,3 residues also seem to contribute to the inhibition of Na v 1.7 by PF-04856264 given the substantial reduction of inhibition with replacement of the equivalent residues from human Na v 1.3. Furthermore, the finding that both Na v 1.3 and Na v 1.7 selective inhibitors interact with similar but not entirely equivalent regions of the Domain 4 S2/S3 transmembrane segment indicates that additional interactions exist, possibly including residues that are conserved across Na v channel subtypes in this region of the voltage sensor domain. . An improved understanding of the functional importance of residues in and around the identified M1,2,3 residues may enable a fuller appreciation of the potential diversity of Na v subtype selective interactions that may be determined by this site.
As described, the dramatic changes in potency of ICA-121431 and PF-04856264 induced by modifications of the M1, M2, or M3 residues are unlikely to result from global structural rearrangements, because inhibition of individual or combined M1,2,3 Na v 1.3 mutants (Na v 1.3-S1510Y/R1511W/E1559D) or Na v 1.7 M123 (Na v 1.7-Y1537S/W1538R/D1586E) by amitriptyline, tetracaine, or TTX was comparable to wild-type channels. Furthermore, the absence of effect on local anesthetic-mediated inhibition suggests that Na v channel inactivation gating is not significantly affected by the M1,2,3 residue modifications. Indeed, an evaluation of the activation and inactivation gating properties of Na v 1.3-S1510Y/R1511W/E1559D or Na v 1.7-Y1537S/W1538R/D1586E are insufficient to account for the pharmacological changes observed.
Interestingly, observed species differences in sensitivity to inhibition by ICA-121431 or PF-04856264 can also be explained by differences in the M1,2,3 residue motif. The variability in species sensitivity to sodium channel inhibitors like the ones described in this study highlight the importance of gathering such information before evaluating compound efficacy and/or toxicity in animal tissues or in vivo models. The present study provides compelling evidence that the unique subtype selective Na v channel inhibitors ICA-121431 and PF-04856264 interact with amino acid residues on an extracellular facing region of the homologous Domain 4 voltage sensor of Na v 1.3 or Na v 1.7, which is distinct from previously described interaction sites for TTX (12, 13) or local anesthetic-like (11, (20) (21) (22) Na v channel inhibitors (Figs. S4 and S5 show homology models illustrating relative locations of interaction sites). However, this small molecule interaction region on Domain 4 does overlap with the interaction sites for a number of polypeptide toxin modulators of sodium channel function (6, 14, 15, 18) . For example, at least one residue, E1559 on Na v 1.3 or D1586 on Na v 1.7 (M3 residue), which contributes to the interaction of both ICA-121431 and PF-04856264, is also important for interaction of site 3 scorpion venom and anemone toxins that slow Na v channel inactivation (14, 15, 18, 35) . The contribution of the M1 and M2 residues to peptide toxin binding is less well defined, although it has been reported that substitution of the tyrosine with alanine at position 1564 of Na v 1.2 (equivalent to M1 residue position described in this study) has no effect on Lqh2 scorpion toxin-induced slowing of inactivation (18) .
Inhibition of Na v channel function via interaction with the voltage sensor region has previously been reported for spider (e.g., Protx II, HWTX-IV) and marine snail (MuO conotoxins) peptide toxins (16, (36) (37) (38) , although much of the published data suggest that they primarily interact with the voltage sensor of homologous Domain 2 (16, 17, (38) (39) (40) . Several recent reports have also described possible interactions of Protx II with Domain 1, 3, and 4 voltage sensors (38) (39) (40) . Interestingly, a residue equivalent to the Domain 4 M3 site on Na v 1.3 and Na v 1.7 has been reported to contribute to the interaction of Protx II, although this site may be more involved in a slowing of inactivation seen with the toxin rather than the more widely described inhibitory action (38) . The mechanistic implications of preferential interactions with specific homologous domain voltage sensor regions by peptide vs. small molecule Na v channel inhibitors remain to be fully explored. However, these differences may underlie the contrasting ability of peptide toxins like Protx II to inhibit Na v channels by shifting the apparent voltage dependence of activation to depolarized potentials vs. apparent stabilization of one or more inactivated conformations by the small molecule inhibitors described in this study.
In conclusion, the present study highlights unique possibilities for identifying additional subtype selective small molecule sodium channel modulators by targeting allosteric interaction sites away from the pore region like those that contribute to voltage sensing and/or conformational changes associated with channel gating. Although the present studies have identified several residues on the Domain 4 voltage sensor region that are important for interaction and selectivity, further investigation is needed to elucidate the full extent of the interaction, perhaps by evaluating other residues reported to participate in peptide modulation of voltage sensor domains. Future studies will also be directed toward better understanding how pharmacological interactions with the voltage sensor in Domain 4 results in inhibition of conduction. Given the proposed involvement of Na v channels in pain, cardiovascular, and central nervous system disorders (9, (41) (42) (43) (44) (45) , further exploration of subtype selective Na v channel inhibitors targeting this unique interaction site may provide opportunities to develop future voltage dependent Na channel directed therapeutics (27) .
Methods
Reagents. ICA-121431 and PF-04856264 were synthesized by the medicinal chemistry group at Icagen Inc. Tetracaine, amitriptyline, and TTX were obtained from Sigma Aldrich.
Generation of Chimeras and Mutants. Chimeric channels comprising human Na v 1.3, Na v 1.5, and Na v 1.7 domains and subdomains were assembled using unique restriction enzyme sites introduced by site-directed mutagenesis in the respective channel coding regions (QuikChange II Site-Directed Mutagenesis and QuikChange Multi Site-Directed Mutagenesis kits; Stratagene). Not I and Sal I restriction sites allowed transfer of full-length cDNA constructs into either pcDNA3.1 (Invitrogen) or pLNCX2 (BD Bioscience Clontech) mammalian expression vectors. All intermediate and final constructs were verified by sequencing and are based on nucleotide numbering from National Center for Biotechnology Information GenBank sequences NM_006922 for hNa v 1.3 and NM_198056 for hNa v 1.5 and NM_002977 for hNa v 1.7. Final constructs were either transiently expressed (domain swap chimeras) or stably expressed (sub-Domain 4 chimeras and all point mutations) in HEK-293 cells. Transient transfections were achieved using Fugene 6 (Roche Applied Science) according to the vendor's protocol. Functional currents were recorded 48 h after transfections. Stable clonal cell lines were selected with G-418 (800 μg/mL) and prioritized by functional sodium current amplitude using conventional patch clamp or the IonWorks high-throughput electrophysiology platform. Controls for the wild-type human Na v 1.3, Na v 1.5, and Na v 1.7 were stably expressed in HEK-293 cells using the same procedures described above.
Electrophysiology. Functional characterization of voltage-gated sodium currents was accomplished using either conventional whole cell patch clamp or PatchXpress or Ionworks Quattro high-throughput electrophysiology platforms (Molecular Devices). Conventional patch clamp. Coverslips containing HEK-293 cells expressing unmodified and mutated Na v channels were placed in a recording chamber on the stage of an inverted microscope and perfused (∼1 mL/min) with an extracellular solution containing 138 mM NaCl, 2 mM CaCl 2 , 5.4 mM KCI, 1 mM MgCl 2 , 10 mM glucose, and 10 mM Hepes (pH 7.4), with NaOH. Recording patch pipettes were filled with an intracellular solution containing 135 mM CsF, 5 mM NaCl, 2 mM MgCl 2 , 10 mM EGTA, and 10 mM Hepes (pH 7.3) with NaOH and had a resistance of 1-2 MΩ. All recordings were made at room temperature (22-24°C) using AXOPATCH 200B amplifiers and PCLAMP software (Molecular Devices). Na v currents were measured using the wholecell configuration of the patch clamp technique. All compounds were dissolved in DMSO to make 10-mM stock solutions, which were then diluted into extracellular solution to attain the final concentrations desired. The final concentration of DMSO (<0.3%) was found to have no significant effect on sodium currents. Test compound effects were evaluated using a protocol in which cells depolarized from a holding potential of −120 mV (or −140 mV for Na v 1.5) to a membrane potential that inactivated half of the available channels for 8 s (determined empirically for each channel type) followed after a 20-ms recovery at −120 mV by a test pulse to 0 mV to assess magnitude of inhibition. Concentration response data were analyzed using nonlinear least-squares fit of the Logistic Equation (GraphPad Prism 5) to provide IC 50 determinations. PatchXpress automated electrophysiological platform. All assay buffers and solutions were identical to those used in conventional whole-cell voltage clamp experiments described above. Na v channel-expressing cells were grown as above to 50-80% confluency and harvested by trypsinization. Trypsinized cells were washed and resuspended in extracellular buffer at a concentration of 1 × 10 6 cells/mL. The onboard liquid handling facility of the PatchXpress was used for dispensing cells and application of test compounds. Test compound effects were evaluated and analyzed using the same protocols used for conventional patch clamp. Ionworks Quattro automated electrophysiological platform. Intracellular and extracellular solutions were as described above with the following changes: 100 μg/mL amphotericin was added to the intracellular solution to perforate the membrane and allow electrical access to the cells. Na v channel-expressing cells were grown and harvested as for PatchXpress, and cells were resuspended in extracellular solution at a concentration of 3-4 × 10 6 cells/mL. The onboard liquid handling of the Ionworks Quattro was used for dispensing cells and application of test compounds. Test compound effects were evaluated using a voltage protocol in which a 500-ms voltage step to 0 mV from −120 mV was applied to fully inactivate available sodium channels, followed after a 50 ms to 100 s hyperpolarized recovery period at −120 mV to allow partial recovery from inactivation, by a test voltage step to 0 mV to assess magnitude of inhibition. This protocol facilitates comparison of channel subtypes independent of their differences in midpoint potentials for voltage dependence of inactivation.
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